Genscript Biotech Statistics

Total Valuation

FRA:G51 has a market cap or net worth of EUR 3.64 billion. The enterprise value is 3.30 billion.

Market Cap	3.64B
Enterprise Value	3.30B

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	2.19B
Shares Outstanding	n/a
Shares Change (YoY)	+4.08%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	0.22%
Owned by Institutions (%)	15.52%
Float	1.38B

Valuation Ratios

The trailing PE ratio is 1.37 and the forward PE ratio is 39.53.

PE Ratio	1.37
Forward PE	39.53
PS Ratio	5.16
PB Ratio	0.97
P/TBV Ratio	0.97
P/FCF Ratio	33.26
P/OCF Ratio	18.69
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 205.72, with an EV/FCF ratio of 30.21.

EV / Earnings	1.25
EV / Sales	4.60
EV / EBITDA	205.72
EV / EBIT	n/a
EV / FCF	30.21

Financial Position

The company has a current ratio of 1.96, with a Debt / Equity ratio of 0.12.

Current Ratio	1.96
Quick Ratio	1.78
Debt / Equity	0.12
Debt / EBITDA	2.20
Debt / FCF	4.27
Interest Coverage	12.85

Financial Efficiency

Return on equity (ROE) is -1.94% and return on invested capital (ROIC) is 2.88%.

Return on Equity (ROE)	-1.94%
Return on Assets (ROA)	2.56%
Return on Invested Capital (ROIC)	2.88%
Return on Capital Employed (ROCE)	3.71%
Revenue Per Employee	122,227
Profits Per Employee	459,259
Employee Count	5,568
Asset Turnover	0.19
Inventory Turnover	8.23

Taxes

In the past 12 months, FRA:G51 has paid 14.98 million in taxes.

Income Tax	14.98M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +24.73% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+24.73%
50-Day Moving Average	1.76
200-Day Moving Average	1.62
Relative Strength Index (RSI)	43.78
Average Volume (20 Days)	15

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, FRA:G51 had revenue of EUR 705.13 million and earned 2.65 billion in profits. Earnings per share was 1.20.

Revenue	705.13M
Gross Profit	391.05M
Operating Income	152.78M
Pretax Income	-36.61M
Net Income	2.65B
EBITDA	201.96M
EBIT	152.78M
Earnings Per Share (EPS)	1.20

Full Income Statement

Balance Sheet

The company has 799.01 million in cash and 467.06 million in debt, giving a net cash position of 331.95 million.

Cash & Cash Equivalents	799.01M
Total Debt	467.06M
Net Cash	331.95M
Net Cash Per Share	n/a
Equity (Book Value)	3.76B
Book Value Per Share	1.73
Working Capital	490.70M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 194.49 million and capital expenditures -85.18 million, giving a free cash flow of 109.31 million.

Operating Cash Flow	194.49M
Capital Expenditures	-85.18M
Free Cash Flow	109.31M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 55.46%, with operating and profit margins of 21.67% and 375.74%.

Gross Margin	55.46%
Operating Margin	21.67%
Pretax Margin	-5.19%
Profit Margin	375.74%
EBITDA Margin	28.64%
EBIT Margin	21.67%
FCF Margin	15.50%

Dividends & Yields

FRA:G51 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-4.08%
Shareholder Yield	-4.08%
Earnings Yield	72.88%
FCF Yield	3.01%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:G51 has an Altman Z-Score of 2.91 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.91
Piotroski F-Score	6